Gastroparesis Treatment Market Revenue to Attain USD 9.99 Bn by 2033

19 Aug 2025

Share :

Table of Content

1. Gastroparesis Treatment Market Revenue and Trends 2025 to 2033 2. Market Overview 3. Segment Insights 4. Regional Insights 5. Gastroparesis Treatment Market Coverage 6. Gastroparesis Treatment Market Key Players

Gastroparesis Treatment Market Revenue and Trends 2025 to 2033

The global gastroparesis treatment market revenue reached USD 6.94 billion in 2025 and is predicted to attain around USD 9.99 billion by 2033 with a CAGR of 4.65%. The market growth is attributed to the increasing prevalence of diabetes and gastrointestinal disorders, coupled with advancements in drug development and improved healthcare access.

Market Overview

The gastroparesis treatment market is experiencing rapid growth, driven by the growing prevalence of gastrointestinal disorders and the increasing global burden of diabetes, a significant risk factor. Growing awareness of early diagnosis and improved access to healthcare are driving the growth of the market. Advances in pharmacological treatments, such as prokinetics, and the emergence of new drug pipelines, alongside minimally invasive surgical approaches, will further spur growth. Older patients are particularly vulnerable to gastric motility disorders, which also contribute to market expansion. Moreover, government support, increased healthcare spending, and continued investment in research will foster innovation and ensure continued market growth.

Segment Insights

• By treatment type, the pharmacological therapy segment led the market in 2024 with the largest share in 2024. This is mainly due to the common use of prokinetic drugs, antiemetics, and newly evolving therapies for gastroparesis treatment. The widespread use of prokinetic and antiemetic drugs as first-line treatments to manage symptoms such as nausea, vomiting, and delayed gastric emptying further boosted their demand.
• By disease type, the diabetic gastroparesis segment sustained dominance in the market in 2024, as it is the most prevalent form of the condition. Rising global diabetes prevalence, as well as the need for effective and evidence-based therapeutic options for gastroparesis, further support segment growth.
• By end user, the hospitals segment dominated the market in 2024 due to their role as primary centers for diagnosis, management, and treatment of moderate to severe cases. Hospitals are often equipped with sophisticated healthcare infrastructure and offer specialized gastroenterology treatment, attracting more patients.
• By distribution channel, the hospital pharmacies segment led the market with a major share in 2024 due to their role as primary centers for diagnosis, management, and treatment of moderate to severe cases. Hospital pharmacies provide patients with easy access to prescribed medications.

Regional Insights

North America registered dominance in the gastroparesis treatment market with the largest revenue share in 2024. This is mainly due to the high incidence of diabetes and gastrointestinal disorders, alongside a robust healthcare infrastructure. The region boasts advanced diagnostics, innovative technologies, and substantial research budgets. Growing awareness of gastroparesis, supportive government initiatives, and rising healthcare budgets further fuel market growth. The presence of leading pharmaceutical companies, coupled with effective reimbursement, enhances treatment access in the U.S. and Canada.

Asia Pacific is expected to experience rapid growth in the gastroparesis treatment market, driven by a rising diabetic population and increased awareness of gastrointestinal health. Developing healthcare infrastructure, improving facility access, and government healthcare initiatives are supporting strong regional demand. An aging population and lifestyle changes, leading to more gastroparesis cases, will stimulate future market growth. Increased clinical research and investment in pharmaceutical development by countries like China, Japan, and India further support market growth.

Gastroparesis Treatment Market Coverage

Recent Development

• In June 2025, CinDome Pharma announced the first patient has been dosed in its Phase 2 EnvisionGI trial evaluating Deudomperidone (CIN-102) for treating idiopathic gastroparesis. (Source: https://cindome.com)

Gastroparesis Treatment Market Key Players

• Medtronic plc
• Allergan plc (now part of AbbVie Inc.)
• AbbVie Inc.
• Takeda Pharmaceutical Company Limited
• Evoke Pharma Inc.
• Neurogastrx, Inc.
• Theravance Biopharma, Inc.
• CinRx Pharma
• Axsome Therapeutics, Inc.
• RaQualia Pharma Inc.
• ANI Pharmaceuticals, Inc.
• Ironwood Pharmaceuticals, Inc.
• Daewoong Pharmaceutical Co., Ltd.
• Processa Pharmaceuticals, Inc.
• Neurogastrix Technologies Ltd.
• Evoke Pharma Inc.
• EndoStim, Inc.
• AbbMed Inc.
• Teva Pharmaceutical Industries Ltd.
• Cadila Healthcare Limited

Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6597

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com |+1 804 441 9344